1.	A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 85 Sponsor: Pharmaceutical / Industry Protocol IDs: BNIT-PRV-301, NCT01322490
2.	153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 070106, 07-C-0106, NCI-07-C-0106, 7678, NCT00450619
3.	Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 070107, 07-C-0107, NCI-07-C-0107, 7354, NCT00450463